Kringle Pharma, Inc. develops and distributes biotechnology products. The Company produces regenerative medicines, cancer therapy medicines, and other products. Kringle Pharma markets its products throughout Japan.

Financial Results For The Fiscal Year Ended September 30, 2025 [Japanese Gaap] (Non-Consolidated)

[Delayed] Kringle Pharma Launches U.S. Subsidiary To Drive Global Growth

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kringle Pharma Inc (4884 JP)

Financial Results For The Fiscal Year Ended September 30, 2025 [Japanese Gaap] (Non-Consolidated)

[Delayed] Kringle Pharma Launches U.S. Subsidiary To Drive Global Growth

Financial Results For The Nine Months Ended June 30, 2025 [Japanese Gaap] (Non-Consolidated)

U.S. Fda Orphan Drug Designation Granted To Recombinant Human Hgf, Kp-100it,For The Treatment Of Acute Spinal Cord Injury

[Delayed] Financial Results For The Six Months Ended March 31, 2025 [Japanese Gaap] (Non-Consolidated)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)